The Fox Tales

Main Menu

  • Home
  • Novel update
  • Novel books
  • Novel story
  • Novel list

The Fox Tales

Header Banner

The Fox Tales

  • Home
  • Novel update
  • Novel books
  • Novel story
  • Novel list
Novel update
Home›Novel update›Sun Pharma Advanced Research: Update on SPARC Strategy and Portfolio

Sun Pharma Advanced Research: Update on SPARC Strategy and Portfolio

By Jack N. Hernandez
December 9, 2021
0
0


SPARC Strategy and Portfolio Update

9e december 2021

BSE: 532872 • NSE: SPARC • BLOOMBERG: SPADV @ IN • REUTERS: SPRC.BO • CIN: L73100GJ2006PLC047837

Warning

This presentation and its content may not be distributed, published or reproduced, in whole or in part, or disclosed by recipients directly or indirectly to any other person. Any breach of these restrictions may constitute a violation of applicable laws. Consequently, anyone in possession of this presentation must inform themselves and respect these restrictions. This presentation may include statements which may constitute forward-looking statements. All statements that deal with expectations or projections regarding the future, including, but not limited to, statements about growth strategy, business development, market position, expenses and financial results, are forward-looking statements. The peak sales forecast / potential in the presentation represents the potential sales of the product (s) to the marketing partner. Forward-looking statements are based on certain assumptions and expectations of future events. This presentation should not be construed as a recommendation or forecast by Sun Pharma Advanced Research Company Limited (“Company”). Please note that the past performance of the Company is not and should not be taken as indicative of future results. The Company cannot guarantee that these assumptions and expectations are correct or will be achieved. Actual results, performance or achievements could therefore differ materially from those projected in these forward-looking statements. The Company does not undertake to revise any forward-looking statements that may be made from time to time by or on behalf of the Company. In light of these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements.

The information contained in these documents has not been independently verified. None of the Company, its directors, promoters or affiliates, nor any of its respective employees, advisers or representatives or any other person accepts any liability whatsoever, whether tort, contractual or otherwise, for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred in any way resulting, directly or indirectly, from any use of this document or its contents or otherwise in connection with this document, and makes no representations or warranties, express or implied, for the contents of this document, including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of between them, or on their behalf, and nothing in this presentation should be taken as a promise or representation in this regard, whether as to the past or the future. The information and opinions contained in this presentation are current, and unless otherwise indicated, as of the date of this presentation. The Company assumes no obligation to update or revise any information or opinions expressed in this presentation as a result of new information, future events or otherwise. Any opinion or information expressed in this presentation is subject to change without notice. This presentation does not constitute or form part of any offer, invitation or inducement to sell or issue, nor any solicitation of an offer to purchase or subscribe for securities of the Company, nor the latter or any part of it. this or the fact of its distribution constitutes the basis of, or may be relied upon in connection with, any contract or commitment in this regard. No person is authorized to give any information or make any statement not contained or inconsistent with this presentation and if given or made, such information or statements should not be considered to have been authorized by any person. By participating in this presentation or accepting any copies of the slides presented, you agree to be bound by the foregoing limitations. All brand names and trademarks are the property of their respective owners.

01

Strategy and portfolio update

02

Anil raghavan

03

Anti TAA-1 and others

04

preclinical programs

Nitin Dame

05 Questions and answers

NCE clinical assets

Siu Long Yao

Financial update

Chetan Rajpara

SPARC – Review of our journey

4 clinical stage programs targeting areas of high unmet need

Targeting large addressable patient populations with a combined maximum sales potential of $ 20 billion or more in 6 indications in oncology, neurology and immunology

Discovery and development through validated and novel biology to balance risk

Multimodal portfolio covering small and large molecules and conjugated entities

More than 10 preclinical programs, including a TAA-1 program, which should enter clinical practice in 2023

Proven high-quality R&D organization with global operations with high return on capital

More than 350 scientists in 4 research centers, including the United States; $ 400M invested to date 2 USFDA approvals for internally developed assets

3 NDAs targeted for submission in 2022

Very flexible model to maximize shareholder value

Partnerships to maximize significant business potential and provide non-dilutive capital

Maximize the multi-TA opportunity and preserve the optionality for spin-offs

Experienced management team and globally recognized scientific advisory board

ADC = Drug Antibody Conjugate | TA = Therapeutic Area | USFDA = United States Food and Drug Administration | NDA = Approval of a new drug | TAA-1 = antigen associated with tumor-1

Differentiated operating model

DISCOVERY

Internal ideation

  • Deliberate process with a robust evaluation framework
  • Mature Discovery Skill with Selected Partnerships to Increase Capabilities

Collaborations with academic and biotechnology institutes

  • Competitive partnership model
  • Strategic relations with several level 1 university institutes around the world
  • Focus on robust internal validation

DEVELOPMENT

Full-service brick and mortar value chain

Significant experience in global development and manufacturing scale-up

Robust Go / No-Go process with substantial experimental and external inputs – Kill early, kill completely

Opportunities to leverage the patient pool in India for rapid clinical PoC, biomarker validation and more

MARKETING

Several assets licensed to partners providing validation for the model

Continue to seek partnerships suited to assets

Strategic flexibility to build its own business engine in the future or create an alternative structure to unleash value

Access high quality early

Translate efficiently by leveraging

Maximize value capture with

bring science to the world

cost and patient arbitration

business models tailored to assets

Low chess cost offers multiple shots on goal for the capital invested

PoC = Proof of Concept

This is an excerpt from the original content. To continue reading it, access the original document here.

Warning

Sun Pharma Advanced Research Company Limited published this content on December 09, 2021 and is solely responsible for the information it contains. Distributed by Public, unedited and unmodified, on 09 December 2021 08:11:02 UTC.

Public now 2021

All news on SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
Sales 2021 2,530 million
33.5 million
33.5 million
Net income 2021 -1 511 million
-20.0 M
-20.0 M
Net debt 2021 2,207 million
29.2 million
29.2 million
PER 2021 ratio -24.6x
Yield 2021 –
Capitalization 66,740 M
885 million
884 million
VE / Sales 2020 33.7x
VE / Sales 2021 15.6x
Number of employees 410
Free float 23.5%

SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED Chart
Duration :

Period :

Sun Pharma Advanced Research Company Limited technical analysis chart |  MarketScreener

Technical Analysis Trends SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED

Short term Mid Road Long term
Tendencies Bearish Neutral Bullish

Evolution of the income statement


Related posts:

  1. COVID-19 update for October 16 and 17: here is the latest news on the coronavirus in British Columbia
  2. Stimulus Update: Didn’t Receive a Child Tax Credit? Check if you are eligible
  3. October 12 – October 18 – Oswego County today
  4. SIGA Technologies will organize a commercial update call in November
Tagsunited states

Categories

  • Novel books
  • Novel list
  • Novel story
  • Novel update

Recent Posts

  • Reacher Season 2 Story Details, Source Material Revealed
  • New Life Updated Wednesday, May 18, 2022
  • Preston House now on endangered historic places list | Community
  • Reed City author uses his mother’s letters to tell his story | News
  • 10 Best Horror Movies Based On Books

Archives

  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • May 2021
  • April 2021
  • February 2021
  • December 2020
  • October 2020
  • September 2020
  • August 2020
  • June 2020
  • March 2020
  • February 2020
  • September 2019
  • June 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • May 2018
  • November 2016
  • September 2016
  • May 2016
  • December 2015
  • September 2015
  • December 2014
  • July 2014
  • May 2014
  • March 2014
  • July 2013
  • Privacy Policy
  • Terms and Conditions